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cost of managing a dry eye patient was $783 in the US from the payers’ perspective, 
with $678, $771, and $1267 for mild, moderate, and severe patients separately. The 
overall direct costs of DED for the health care system was $3.84 billion based on the 
prevalence of DED. The average annual direct cost for self-treated patients using OTC 
treatment or nutritional supplements was estimated as $126 per patient. The annual 
productivity loss per full-time worker with DED ranges from $12, 569 to $18,168 
depending on the severity of symptoms. The sensitivity analysis suggested that the 
estimated mean direct cost per DED patient seeking professional medical care ranges 
from $757 to $809 approximately. Multiple one-way sensitivity analysis suggested 
the cost estimate was most sensitive to the variation in the distribution of severity of 
symptoms, the frequency of ophthalmologist visits, prevalence of the combined use of 
punctal plugs and cyclosporine, the frequency of optometrist, and compliance with 
cyclosporine by severe patients. CONCLUSIONS: DED poses a substantial amount 
of economic burden for the payer and the society with the indirect costs substantially 
outweighing the direct costs.
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OBJECTIVES: To determine the cost-effective threshold price of the AcrySof Cachet 
phakic intraocular lens (PIOL) relative to the currently marketed Visian and Artisan 
PIOLs in the US. METHODS: We developed a Markov cost-effectiveness model that 
compared the Cachet to the Visian and Artisan PIOLs in a hypothetical cohort of 
patients with moderate to high myopia. A payer perspective was adopted. Costs and 
effectiveness results were discounted at 3% over a 40 year time horizon. Effectiveness 
was expressed as vision adjusted life years (VALYs). VALYs represent a quantiﬁcation 
of the beneﬁts derived from various levels of visual acuity (VA) accumulated over time. 
VA outcome probabilities were taken directly from the CE Mark (Cachet) and FDA 
approved PIOL product labels. The prices of the Visian and Artisan PIOLs were $750 
and $695 respectively. Patients with less than 20/20 VA were assumed to require either 
glasses and/or contact lenses. PIOL, contact lenses and eye glasses costs were based 
on 2009 data from MarketScope and the Vision Watch Report. Probabilities for 
adverse events and associated procedures were derived from PIOL product labels and 
physician interviews. Surgical and drug costs were estimated using reference based 
physician fee estimates and the Medi-Span Price Rx database. Uncertainty was 
addressed through univariate and probabilistic sensitivity analysis (PSA). RESULTS: 
The base-case cost-effectiveness model indicated that the Cachet PIOL economically 
dominated the Visian PIOL up to a threshold price of $1587, and the Artisan PIOL 
up to a threshold price of $2373. The PSA showed that at these prices, the probabilities 
that the Cachet dominated were 59% and 63% respectively. CONCLUSIONS: Given 
its greater efﬁcacy and favourable adverse events proﬁle, the Cachet PIOL was eco-
nomically dominant up to a price twice that of the Visian PIOL and three times that 
of the Artisan PIOL with a considerable degree of certainty.
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OBJECTIVES: To examine whether terbinaﬁne or itraconazole is a more cost-effective 
treatment for onychomycosis in an institutional setting in Mexico. METHODS: A 
cost-effectiveness analysis was designed; a decision tree with bayesian approach was 
used to model the cost-effectiveness of terbinaﬁne vs. itraconazole in the treatment of 
onychomycosis in Mexico. The perspective was from the Mexican Institute of Social 
Security (IMSS). Discount rate was not used because the time horizon was less than 
1 year. Resource use data was taken from IMSS. Cost data for medications was 
obtained from a local drug distributor database (NADROSA Aug 2009), assuming 
terbinaﬁne dosing scheme as 250 mg daily for 3 months, and itraconazole dosing 
scheme as 400 mg daily for 7 days every 4 weeks for 3 months (pulse dosing scheme). 
Cost data for physician consult was estimated as a ﬁxed-variable. As this analysis was 
performed from an institutional perspective, no other costs were identiﬁed to be 
required for the treatment of onychomycosis. Using data from the L.I.O.N. clinical 
study, mycological cure success rates were estimated for both treatments as ﬁrst 
options; for mycological cure failures, re-treatment costs were estimated using a second 
terbinaﬁne scheme in both groups and an additional physician consult. Total costs per 
patient were determined and incremental cost-effectiveness ratios were calculated. A 
Monte Carlo (100,000 iterations) simulation was performed to reduce the error <0.03. 
A probabilistic sensitivity analysis was performed. RESULTS: The incremental cost 
analysis revealed a total cost of $3823 for terbinaﬁne vs. $7152 for itraconazole (both 
in Mexican pesos, p < 0.001) per patient successfully treated. Terbinaﬁne provides 
superior total health beneﬁts than itraconazole regardless of willingness to pay. The 
sensitivity analysis conﬁrmed the robustness of the model. CONCLUSIONS: From an 
institutional perspective, terbinaﬁne is a more cost-effective (dominant) choice than 
itraconazole for treating onychomycosis in Mexico.
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OBJECTIVES: To assess from a societal perspective whether isotretinoin (13-cis-ret-
inoic acid) or oral antibiotics in combination with topical preparations is the more 
cost-effective ﬁrst-line treatment of moderate-to-severe acne vulgaris. METHODS: A 
decision-tree model was used to simulate therapy costs and effectiveness. All estimates 
of cost and effectiveness were obtained from the literature or expert opinion. The 
cost-effectiveness ratio was reported as incremental cost per quality-adjusted life-year 
(QALY) gained. The time horizon was 2 years. Costs and QALYs were discounted by 
a monthly rate of 0.0025%, which is equivalent to an annual rate of 3%. All costs 
were adjusted to 2009 US dollars. A one-way sensitivity analysis was used to determine 
the robustness of the model’s results. The model was developed using Microsoft Excel. 
RESULTS: Isotretinoin increases discounted costs by $1,486 and discounted QALYs 
by 0.071 years when compared to conventional therapy of oral antibiotics and topical 
preparations. This resulted in an incremental cost-effectiveness ratio (ICER) of 
$20,930 per QALY gained for the base case. The results of the model were insensitive 
to most model parameters except for the probabilities associated with achieving 
adequate response or relapse while on therapy. The biggest change in the ICER (204% 
increase) was caused by a 17% increase in the probability of maintaining adequate 
response (no relapse) with conventional therapy. Although the ICER was sensitive to 
these probability values, the highest ICER value of $63,602/QALY found from the 
sensitivity analysis was still below the threshold for cost-effectiveness. CONCLU-
SIONS: Isotretinoin was more costly and also more effective than conventional 
therapy. These results did not change when model parameters were varied in the 
sensitivity analysis. Assuming a $120,000/QALY threshold for cost-effectiveness, 
isotretinoin was cost-effective in the ﬁrst-line treatment of moderate-to-severe inﬂam-
matory acne.
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OBJECTIVES: Glaucoma, a chronic disorder that requires lifelong treatment, creates 
a ﬁnancial burden on patient and health care payers. This study compared ﬁxed-
combination therapies in patients with open-angle glaucoma, namely, Latanoprost 
with Timolol (LT), Dorzolamide with Timolol (DT), and Brimonidine with Timolol 
(BT). METHODS: A cost effectiveness analysis was conducted by extracting data from 
published literature and primary data collected from pharmacy stores. The study was 
conducted from a managed care perspective with drug utilization for a period of 12 
months. A decision analytic model was developed and incremental cost-effectiveness 
ratios (ICER) were calculated. Therapy cost was calculated by considering medication 
cost (by taking an average reimbursement amount provided by Medicare part D and 
private insurances), physician visit cost, cost associated with adverse drug events, and 
cost due to lack of patient persistency (based on expected annual drug usage). Effec-
tiveness measure considered was percent reduction in intraocular pressure (IOP) from 
baseline. A one-way sensitivity analysis was performed by varying cost by 25% to 
take into consideration the potential wastage, overutilization, underutilization, and 
various differences in IOP reduction in patients. RESULTS: Mean average percent IOP 
reduction for LT, DT and BT was 6.3%, 4.3% and 4.6%, respectively. The total cost 
of therapy for LT, DT and BT was estimated to be $711, $935, and $1099, respec-
tively. ICER analyses indicated a gain of $111.5 for change from DT to LT, while a 
change from BT to LT indicated a gain of $228. The results remained robust after 
sensitivity analysis. CONCLUSIONS: In our study, LT was found to be more cost-
effective compared to DT and BT. Managed care payers may wish to prioritize ﬁxed-
combination therapies used for glaucoma considering medication related adverse 
events and persistency. Further, research taking into account various other costs 
should be conducted to provide better evidence.
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OBJECTIVES: Psoriasis is a chronic and incurable systemic inﬂammatory disease with 
devastating impact on overall health of patients. Ustekinumab, a fully human mono-
clonal antibody, is the ﬁrst treatment to speciﬁcally target IL-12 and IL-23.The efﬁcacy 
and safety of ustekinumab have been studied in three Phase III, international, ran-
domised, controlled clinical trials and its clinical superiority over etanercept was 
demonstrated in a Phase III trial (ACCEPT). The objective of this study was to 
compare cost efﬁcacy of subcutaneously administered biologics by using a cost per 
responder model in Turkey. The study was undertaken from a Turkish health care 
payer perspective. METHODS: In the cost per responder model, clinical efﬁcacy was 
measured by improvement in the Psoriasis Area and Severity Index (PASI 75 response) 
from randomized, controlled trials. An indirect comparison using a Mixed Treatment 
Comparison (MTC) meta-analysis was used to estimate response rates. Comparators 
used in the model were ustekinumab, etanercept, adalimumab, and efalizumab. 
Ustekinumab efﬁcacy has been analyzed based on patient’s weight for patients with a 
